| Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer (NCT03658434) | Zealand University Hospital | 2018-08-01 |
| Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) (NCT03076203) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-09-22 |
| The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment (NCT02955082) | Institute of Cancer Research, United Kingdom | 2017-05-25 |
| Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer (NCT03016741) | Northwestern University | 2017-03-31 |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (NCT02691975) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-12 |
| Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer (NCT02288936) | Spanish Oncology Genito-Urinary Group | 2015-02-05 |
| Molecular Phenotype Changes and Personalized Treatment for CRPC (NCT02208583) | Tianjin Medical University Cancer Institute and Hospital | 2014-06-01 |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer (NCT01631552) | Gilead Sciences | 2012-12-17 |
| Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer (NCT01741116) | Korean Cancer Study Group | 2012-11-01 |
| Study of Weekly Cabazitaxel for Advanced Prostate Cancer (NCT01518283) | Spanish Oncology Genito-Urinary Group | 2012-05-01 |
| Radiotherapy vs Observation for CRPC (NCT01590498) | Zhengzhou University | 2012-05-01 |
| Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer (NCT01487863) | Dendreon | 2011-12-01 |
| Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (NCT01422850) | CytoVac A/S | 2011-08-01 |
| Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel (NCT01260688) | National Cancer Institute (NCI) | 2010-10-01 |
| Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy (NCT01450683) | Stanford University | 2010-09-01 |
| Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer (NCT01215799) | CytRx | 2010-08-01 |
| TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) (NCT01194960) | Oxford BioMedica | 2010-08-01 |
| A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (NCT01083615) | Achieve Life Sciences | 2010-03-01 |
| Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer (NCT01020305) | Sandy Srinivas | 2009-10-01 |
| Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer (NCT00928252) | Queen's Medical Center | 2009-06-01 |
| RNActive®-Derived Therapeutic Vaccine (NCT00906243) | University of Florida | 2009-05-01 |
| Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (NCT00891345) | CytoVac A/S | 2009-04-01 |
| Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer (NCT00795171) | Medical University of Vienna | 2008-11-01 |
| A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (NCT00699751) | Bayer | 2008-06-12 |
| Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients (NCT00636740) | Merrion Pharmaceuticals, LLC | 2008-02-01 |
| Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer (NCT00583024) | David M Lubaroff | 2007-12-01 |
| A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer (NCT00525408) | Cadila Pharnmaceuticals | 2007-11-01 |
| A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) (NCT00571675) | Ascenta Therapeutics | 2007-10-01 |
| Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer (NCT00570700) | University of California, Irvine | 2007-07-01 |
| Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients (NCT00411853) | Sheba Medical Center | 2007-06-01 |
| A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients (NCT00675545) | National University Hospital, Singapore | 2007-05-01 |
| ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer (NCT00477529) | Celgene | 2007-04-01 |
| Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy (NCT00407251) | British Columbia Cancer Agency | 2007-02-01 |
| Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00337077) | National Cancer Institute (NCI) | 2006-11-01 |
| A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer (NCT00448734) | Poniard Pharmaceuticals | 2006-06-01 |
| Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone (NCT00493766) | Novartis Pharmaceuticals | 2006-05-01 |
| PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC (NCT00313482) | Veeda Oncology | 2006-04-01 |
| Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer (NCT00286091) | Amgen | 2006-01-24 |
| A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (NCT00286806) | Ascenta Therapeutics | 2005-12-01 |
| RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer (NCT00629525) | Daniel George, MD | 2005-08-01 |
| BAY88-8223, Does Response Study in HRPC Patients (NCT00667199) | Bayer | 2005-05-30 |
| Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen (NCT00069745) | Agennix | 2003-09-01 |
| A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer (NCT00156884) | Alberta Health services | 2003-08-01 |
| An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer (NCT00201357) | National Health Research Institutes, Taiwan | 2002-10-01 |
| Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate (NCT00151073) | University of Michigan Rogel Cancer Center | 2002-04-01 |
| Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer (NCT01133704) | Dendreon | 2000-05-01 |
| Study Evaluating the Safety and Tolerability of L-377202 (NCT00987753) | University of Alabama at Birmingham | 1999-03-01 |
| Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel (NCT00082134) | Genzyme, a Sanofi Company | |
| YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy (NCT00048659) | Astellas Pharma Inc | |